Literature DB >> 26920069

αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease.

Ana Osório Oliveira1, Alexander Osmand2, Tiago Fleming Outeiro3, Paul Joseph Muchowski4, Steven Finkbeiner5.   

Abstract

Huntington's disease (HD) is caused by an expanded polyglutamine (polyQ) tract in the huntingtin (htt) protein. The polyQ expansion increases the propensity of htt to aggregate and accumulate, and manipulations that mitigate protein misfolding or facilitate the clearance of misfolded proteins are predicted to slow disease progression in HD models. αB-crystallin (αBc) or HspB5 is a well-characterized member of the small heat shock protein (sHsp) family that reduces mutant htt (mhtt) aggregation and toxicity in vitro and in Drosophila models of HD. Here, we determined if overexpressing αBc in vivo modulates aggregation and delays the onset and progression of disease in a full-length model of HD, BACHD mice. Expression of sHsps in neurodegenerative disease predominantly occurs in non-neuronal cells, and in the brain, αBc is mainly found in astrocytes and oligodendrocytes. Here, we show that directed αBc overexpression in astrocytes improves motor performance in rotarod and balance beam tests and improves cognitive function in the BACHD mice. Improvement in behavioral deficits correlated with mitigation of neuropathological features commonly observed in HD. Interestingly, astrocytic αBc overexpression was neuroprotective against neuronal cell loss in BACHD brains, suggesting αBc might be acting in a non-cell-autonomous manner. At the protein level, αBc decreased the level of soluble mhtt and decreased the size of mhtt inclusions in BACHD brain. Our results support a model in which elevating astrocytic αBc confers neuroprotection through a potential non-cell-autonomous pathway that modulates mhtt aggregation and protein levels.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26920069      PMCID: PMC4986324          DOI: 10.1093/hmg/ddw028

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  81 in total

1.  The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation.

Authors:  M C Kamradt; F Chen; V L Cryns
Journal:  J Biol Chem       Date:  2001-03-23       Impact factor: 5.157

2.  Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA.

Authors:  Isabelle Gourfinkel-An; Miquel Vila; Baptiste Faucheux; Charles Duyckaerts; François Viallet; Jean-Jacques Hauw; Alexis Brice; Yves Agid; Etienne C Hirsch
Journal:  J Neurochem       Date:  2002-02       Impact factor: 5.372

3.  Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils.

Authors:  P J Muchowski; G Schaffar; A Sittler; E E Wanker; M K Hayer-Hartl; F U Hartl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.

Authors:  J M Warrick; H Y Chan; G L Gray-Board; Y Chai; H L Paulson; N M Bonini
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

5.  Psychomotor, executive, and memory function in preclinical Huntington's disease.

Authors:  J S Snowden; D Craufurd; J Thompson; D Neary
Journal:  J Clin Exp Neuropsychol       Date:  2002-04       Impact factor: 2.475

6.  Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.

Authors:  A Wyttenbach; J Carmichael; J Swartz; R A Furlong; Y Narain; J Rankin; D C Rubinsztein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

7.  Neuropsychiatric aspects of Huntington's disease.

Authors:  J S Paulsen; R E Ready; J M Hamilton; M S Mega; J L Cummings
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

8.  Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans.

Authors:  S H Satyal; E Schmidt; K Kitagawa; N Sondheimer; S Lindquist; J M Kramer; R I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

9.  Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.

Authors:  N R Jana; M Tanaka; G h Wang; N Nukina
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

10.  Alterations in the mouse and human proteome caused by Huntington's disease.

Authors:  Claus Zabel; Daniel C Chamrad; Josef Priller; Ben Woodman; Helmut E Meyer; Gillian P Bates; Joachim Klose
Journal:  Mol Cell Proteomics       Date:  2002-05       Impact factor: 5.911

View more
  21 in total

1.  The noncanonical small heat shock protein HSP-17 from Caenorhabditis elegans is a selective protein aggregase.

Authors:  Manuel Iburg; Dmytro Puchkov; Irving U Rosas-Brugada; Linda Bergemann; Ulrike Rieprecht; Janine Kirstein
Journal:  J Biol Chem       Date:  2020-01-30       Impact factor: 5.157

2.  Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Authors:  Yang Yang; Su Yang; Jifeng Guo; Yiting Cui; Beisha Tang; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci       Date:  2017-08-18       Impact factor: 6.167

3.  Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model.

Authors:  Tara E Wood; Joshua Barry; Zhenquin Yang; Carlos Cepeda; Michael S Levine; Michelle Gray
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

Review 4.  Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.

Authors:  Marta Daniela Costa; Patrícia Maciel
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

5.  Mutant Huntingtin Inhibits αB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes.

Authors:  Yan Hong; Ting Zhao; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci       Date:  2017-09-11       Impact factor: 6.167

6.  Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells.

Authors:  Jeffrey M Lynch; Bing Li; Parvaneh Katoli; Chuanxi Xiang; Barrett Leehy; Nalini Rangaswamy; Veronica Saenz-Vash; Y Karen Wang; Hong Lei; Thomas B Nicholson; Erik Meredith; Dennis S Rice; Ganesh Prasanna; Amy Chen
Journal:  J Biol Chem       Date:  2018-11-02       Impact factor: 5.157

7.  Early dysfunction and progressive degeneration of the subthalamic nucleus in mouse models of Huntington's disease.

Authors:  Jeremy F Atherton; Eileen L McIver; Matthew Rm Mullen; David L Wokosin; D James Surmeier; Mark D Bevan
Journal:  Elife       Date:  2016-12-20       Impact factor: 8.140

8.  Differentiation Drives Widespread Rewiring of the Neural Stem Cell Chaperone Network.

Authors:  Willianne I M Vonk; T Kelly Rainbolt; Patrick T Dolan; Ashley E Webb; Anne Brunet; Judith Frydman
Journal:  Mol Cell       Date:  2020-04-07       Impact factor: 17.970

Review 9.  AlphaB-crystallin and breast cancer: role and possible therapeutic strategies.

Authors:  Daniela Caporossi; Attilio Parisi; Cristina Fantini; Elisa Grazioli; Claudia Cerulli; Ivan Dimauro
Journal:  Cell Stress Chaperones       Date:  2020-10-28       Impact factor: 3.667

10.  The engineered expression of secreted HSPB5-Fc in CHO cells exhibits cytoprotection in vitro.

Authors:  Jing Li; Jingjing Yu; Wenxian Xue; Huili Huang; Longjun Yan; Fan Sang; Shuangshuang An; Jing Zhang; Mingli Wang; Jun Zhang; Hui Li; Xiukun Cui; Jiang He; Yanzhong Hu
Journal:  BMC Biotechnol       Date:  2021-06-14       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.